Trials / Conditions / Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
7 registered clinical trials studyying Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Trea NCT06015880 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19 NCT06238648 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619 | Nathan Denlinger | Phase 1 |
| Recruiting | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma NCT05755087 | Lapo Alinari | Phase 1 |
| Active Not Recruiting | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymph NCT05359211 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lympho NCT03984448 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |